亚盛医药:新药利沙托克拉获中国NMPA附条件批准上市

华尔街见闻
Jul 10

亚盛医药(06855)公告要点解读核心事件新药获批上市:公司自主研发的新型Bcl-2抑制剂利沙托克拉(利生妥)获中国NMPA附条件批准上市,成为中国首个上市用于治疗CLL/SLL的Bcl-2抑制剂,全球第二个上市的同类药物。关键要点适应症:用于治疗既往经过至少包含BTK抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)患者临床数据:基于关键注册II期临床研究结果...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10